Compare Robinhood Markets, Inc. (HOOD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Moderna, Inc. — how do they compare? Robinhood Markets, Inc. trades at $109.15 (market cap $96.21B), while Moderna, Inc. trades at $225.16 (market cap $78.65B). The key difference: Robinhood Markets, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Moderna, Inc. for 59 Days on average.
| HOOD | MRNA | |
|---|---|---|
Market Cap | $96.21B | $78.65B |
Volume | 22,572,153 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $152.46 | $203.46 |
52-Week Low | $65.16 | $22.36 |
Typical Hold Time | 75 Days | 59 Days |
Enterprise Value | $102.75B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $109.02, down 0.45% on the day, with a bullish technical signal and strong support at $105. The company reported robust 2025 results with revenue of $4.47B and net income of $1.88B, though valuation ratios like a P/E of 47.35 remain elevated. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at driving growth.
The outlook is positive with a consensus price target of $137.53, implying 26% upside, supported by analyst optimism and product innovation. Key risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny over new offerings like leveraged crypto trading, which could impact investor sentiment and stock performance.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
